These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7769297)

  • 1. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.
    Powers DC; Smith GE; Anderson EL; Kennedy DJ; Hackett CS; Wilkinson BE; Volvovitz F; Belshe RB; Treanor JJ
    J Infect Dis; 1995 Jun; 171(6):1595-9. PubMed ID: 7769297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.
    Treanor JJ; Betts RF; Smith GE; Anderson EL; Hackett CS; Wilkinson BE; Belshe RB; Powers DC
    J Infect Dis; 1996 Jun; 173(6):1467-70. PubMed ID: 8648221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.
    Lakey DL; Treanor JJ; Betts RF; Smith GE; Thompson J; Sannella E; Reed G; Wilkinson BE; Wright PF
    J Infect Dis; 1996 Oct; 174(4):838-41. PubMed ID: 8843225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.
    Treanor JJ; Schiff GM; Hayden FG; Brady RC; Hay CM; Meyer AL; Holden-Wiltse J; Liang H; Gilbert A; Cox M
    JAMA; 2007 Apr; 297(14):1577-82. PubMed ID: 17426277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge.
    Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML
    J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
    Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M
    Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines.
    Quinnan GV; Schooley R; Dolin R; Ennis FA; Gross P; Gwaltney JM
    Rev Infect Dis; 1983; 5(4):748-57. PubMed ID: 6622889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus.
    Powers DC; McElhaney JE; Florendo OA; Manning MC; Upshaw CM; Bentley DW; Wilkinson BE
    J Infect Dis; 1997 Feb; 175(2):342-51. PubMed ID: 9203655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
    J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ
    J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule.
    Couch RB; Webster RG; Kasel JA; Cate TR
    J Infect Dis; 1979 Oct; 140(4):553-9. PubMed ID: 92511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.
    Keitel WA; Cate TR; Atmar RL; Turner CS; Nino D; Dukes CM; Six HR; Couch RB
    Clin Diagn Lab Immunol; 1996 Sep; 3(5):507-10. PubMed ID: 8877126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen.
    Gregoriadis G; Tan L; Ben-Ahmeida ET; Jennings R
    Vaccine; 1992; 10(11):747-53. PubMed ID: 1441730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the potential use of inactivated influenza centrifuged vaccines with various hemagglutinin levels for immunizing schoolchildren].
    Slobodeniuk AV; Shadrin AS; Andrievskaia RA; Aleksandrova NN
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Nov; (11):52-6. PubMed ID: 3434050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
    Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL
    J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children.
    Groothuis JR; Lehr MV; Levin MJ
    Vaccine; 1994 Feb; 12(2):139-41. PubMed ID: 8147095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults.
    Atmar RL; Keitel WA; Cate TR; Quarles JM; Couch RB
    J Infect Dis; 1995 Jul; 172(1):253-7. PubMed ID: 7797925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.